Continuous glucose monitoring of steroid-induced hyperglycemia in patients with dermatologic diseases
Open accessAbstract
Background and Objectives: Systemic administration of glucocorticoids is a mainstay therapy for various inflammatory diseases and may lead to hyperglycemia, which carries the risk of worsening preexisting diabetes and triggering steroid-induced diabetes. Therefore, we aimed to identify patients at risk and to quantify severity of steroid-induced hyperglycemia (SIH) by continuous glucose monitoring (CGM) in hospitalized patients needing systemic glucocorticoid treatment. Patients and Methods: This prospective study included 51 steroid-naive, dermatological patients requiring systemic high-dose glucocorticoid treatment at the Department of Dermatology of the University Hospital Essen. After careful diabetes-specific assessment at admission, glucose monitoring was performed using a CGM system and glucose profile was analyzed in patients with and without SIH. Results: SIH occurred in 47.1% of all treated patients, and a relevant part of patients with initial normoglycemia developed SIH (2/10 patients). Doubling of SIH incidence was observed with each severity grade of dysglycemia (4/10 in prediabetes; 9/10 in diabetes). Patients with SIH spend nearly 6 hours daily above targeted glucose range, and severe hyperglycemia was observed for 1.2 hours/day. Conclusions: Our study underlines the need for dedicated glucose monitoring in dermatologic patients on systemic glucocorticoid therapy by demonstrating its impact on glucose metabolism.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The prevalence of consistent use of glucocorticoid therapy in hospitalized individuals can approach 10-15%, and these medications can induce hyperglycemia in 56-86% of these individuals with and without preexisting diabetes.
“The prevalence of consistent use of glucocorticoid therapy in hospitalized individuals can approach 10-15%, and these medications can induce hyperglycemia in 56-86% of these individuals with and without preexisting diabetes (124-126).”
From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [126]
The Introduction (page unavailable) estimates glucocorticoid therapy in 10% of hospitalized patients and says it can worsen preexisting diabetes or trigger new diabetes. The Discussion (page unavailable) reports that 86% of steroid-treated patients may experience at least one hyperglycemic episode. The paper does not give the claimed 15% therapy prevalence or 56% lower bound for hyperglycemia. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Immune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846 · see citing works
Charleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261 · see citing works
Glucose Variability: A Review of Clinical Applications and Research Developments
Rodbard, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0092 · Cited by 154 · see citing works
Kyi, M., Colman, P. G., Wraight, P. R., Reid, J., Gorelik, A., Galligan, A., Kumar, S., Rowan, L. M., Marley, K. A., Nankervis, A. J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2342 · Cited by 86 · see citing works
The financial impact of an inpatient diabetes management service
Haque, W. Z., Demidowich, A. P., Sidhaye, A., Golden, S. H., & Zilbermint, M. (2021) · Current Diabetes Reports · doi:10.1007/s11892-020-01374-0 · Cited by 48 · see citing works
Flagged first, then by citations
Research works printed but not linked: 18
- [2]Pichardo-Lowden AR Fan CY Gabbay RA. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr Pract. 2011; 17(2): 249- 260. 21041168
- [3]Liu XX Zhu XM Miao Q Ye HY Zhang ZY Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014; 65(4): 324- 332. 25402408
- [4]Suh S Park MK. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab (Seoul). 2017; 32(2): 180- 189. 28555464 PMC5503862
- [5]Fardet L Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs. 2014; 74(15): 1731- 1745. 25204470
- [6]Laugesen K Jørgensen JOL Sørensen HT Petersen I. Systemic glucocorticoid use in Denmark: a population-based prevalence study. BMJ Open. 2017; 7(5): e015237. PMC5729989 28554927
- [8]Radhakutty A Burt MG. Management of endocrine disease: critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia. Eur J Endocrinol. 2018; 179(4): 207- 218. 30299889
- [9]John WG. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med 2012; 29(11):1350-7. 22957983
- [10]American Diabetes Association. Introduction: standards of medical care in diabetes—2022. Diabetes Care. 2021; 45(suppl 1): S1- S2. 34964812
- [12]Tamez-Pérez HE Quintanilla-Flores DL Rodríguez-Gutiérrez R González-González JG Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015; 6(8): 1073- 1081. 26240704 PMC4515447
- [13]Healy SJ Nagaraja HN Alwan D Dungan KM. Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies. Endocrine. 2017; 56(1): 90- 97. 28058528
- [14]Uzu T Harada T Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007; 105(2): c54- c57. 17135768
- [15]El-Darouti MA Mashaly HM El-Nabarawy E, et al. Comparative study of the effect of a daily steroid regimen versus a weekly oral pulse steroid regimen on morphological changes, blood sugar, bone mineral density and suprarenal gland activity. J Dermatolog Treat. 2012; 23(1): 4- 10. 20819024
- [16]German CA Laughey B Bertoni AG Yeboah J. Associations between BMI, waist circumference, central obesity and outcomes in type II diabetes mellitus: the ACCORD trial. J Diabetes Complications. 2020; 34(3): 107499. 31813770
- [18]Holzer G Straßegger B Volc-Platzer B. [Cutaneous manifestations of metabolic syndrome]. Hautarzt. 2016; 67(12): 982- 988. 27815622
- [19]de Macedo GM Nunes S Barreto T. Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. Diabetol Metab Syndr. 2016; 8(1): 63. 27583022 PMC5006568
- [20]Bulger DA Minhas S Asbeutah AA, et al. Chronic systemic inflammatory skin disease as a risk factor for cardiovascular disease. Curr Probl Cardiol. 2021; 46(5): 100799. 33607473
- [23]Curkendall SM Natoli JL Alexander CM Nathanson BH Haidar T Dubois RW. Economic and clinical impact of inpatient diabetic hypoglycemia. Endocr Pract. 2009; 15(4): 302- 312. 19502209
- [24]glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit. Diabetes Care. 2020; 43(9): 2153- 2160. 32669277 PMC7440900
Cited by
Sorted by citations
16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s016 · Cited by 80 · see citing works
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63 · see citing works
- Authors
- Kleinhans, M., Albrecht, L. J., Benson, S., Fuhrer, D., Dissemond, J., & Tan, S.
- Affiliations
- Essen University Hospital (DE)
- Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- Corresponding author
- Tan, Susanne
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2023-01-05
- Volume
- 18
- Issue
- 4
- Pages
- 904-910
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC11307234
- OpenAlex
- W4313545586
- Cited by
- 19
- References
- 5
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 4
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Diabetes Science and Technology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- steroid-induced hyperglycemia, continuous glucose monitoring, glucocorticoids, systemic corticosteroid therapy, skin diseases, prediabetes, diabetes mellitus, glucose metabolism, hospitalized patients
- MeSH terms
- Continuous Glucose Monitoring, Adult, Aged, Blood Glucose, Female, Glucocorticoids, Humans, Hyperglycemia, Male, Middle Aged, Prospective Studies, Skin Diseases, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
